H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on Ironwood Pharma (NASDAQ:IRWD) on Monday, setting a price target of $11, which is approximately 7.95% above the present share price of $10.19.
Selvaraju expects Ironwood Pharma to post earnings per share (EPS) of $0.02 for the second quarter of 2020.
The current consensus among 5 TipRanks analysts is for a Hold rating of shares in Ironwood Pharma, with an average price target of $12.6.
The analysts price targets range from a high of $15 to a low of $11.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $79.94 million and a net profit of $13.23 million. The company's market cap is $1.62 billion.
According to TipRanks.com, H.C. Wainwright analyst Ram Selvaraju is a 5-star analyst with an average return of 22.1% and a 55.8% success rate.
Ironwood Pharmaceuticals , Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.